Prime Medicine (PRME) Operating Leases (2021 - 2026)

Prime Medicine's Operating Leases history runs 6 years deep, the most recent figure standing at $114.5 million for Q1 2026.

• Quarterly Operating Leases rose 1982.04% year-over-year to $114.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.5 million (up 1982.04% YoY) and the FY2025 annual result came in at $108.3 million, up 191.26% from the prior year.
• Operating Leases was $114.5 million for Q1 2026 at Prime Medicine, up from $108.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $118.1 million in Q3 2025 and bottomed at $4.4 million in Q4 2023.
• A 5-year average of $47.5 million and a median of $33.6 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases sank 83.63% — and 2026, when it soared 1982.04%.
• Prime Medicine's Operating Leases stood at $17.1 million in 2022, then tumbled by 74.45% to $4.4 million in 2023, then jumped by 753.34% to $37.2 million in 2024, then jumped by 191.26% to $108.3 million in 2025, then advanced by 5.75% to $114.5 million in 2026.
• Business Quant data shows PRME's Operating Leases at $114.5 million in Q1 2026, $108.3 million in Q4 2025, and $118.1 million in Q3 2025.